| Literature DB >> 31883050 |
Louise Carstam1,2, Isabelle Rydén3,4, Sasha Gulati5,6, Bertil Rydenhag7,3, Roger Henriksson8, Øyvind Salvesen9, Anja Smits3,4,10, Asgeir Store Jakola7,3,6.
Abstract
BACKGROUND: Despite aspirations to achieve equality in healthcare we know that socioeconomic differences exist and may affect treatment and patient outcome, also in serious diseases such as cancer. We investigated disparities in neurosurgical care and outcome for patients with low-grade glioma (LGG).Entities:
Keywords: Brain neoplasm; Diffuse low-grade glioma; Equal care; Glioma/surgery; Neurosurgery; Social disparities
Mesh:
Year: 2019 PMID: 31883050 PMCID: PMC6971149 DOI: 10.1007/s11060-019-03378-7
Source DB: PubMed Journal: J Neurooncol ISSN: 0167-594X Impact factor: 4.130
Clinico-pathological factors related to surgical treatment for diffuse, low-grade gliomas in relation to income levels of patients
| Income level | p-value | |||
|---|---|---|---|---|
| Lower n = 179 | Intermediate n = 186 | Higher n = 177 | ||
| Age, mean (SD) | 47.7 (18.2) | 45.6 (14.1) | 46.0 (11.6) | 0.35 |
| Asymptomatic, n (%) | 14 (8.3) N = 169 | 10 (5.7) N = 176 | 13 (7.6) N = 171 | 0.62 |
| Focal deficit | 76 (43.9) N = 173 | 60 (33.0) N = 182 | 61 (35.3) N = 173 | 0.08 |
| WHO functional statusa, n (%) | 0.002 | |||
| 0: Fully active | 84 (48.6) | 110 (60.4) | 105 (60.3) | |
| 1: Light work possible | 44 (25.4) | 52 (28.6) | 39 (22.4) | |
| 2: Cares for self | 29 (16.8) | 17 (9.3) | 25 (14.4) | |
| 3: Limited self care | 13 (7.5) | 2 (1.1) | 2 (1.1) | |
| 4: Disabled, confined to bed | 3 (1.7) N = 173 | 1 (0.5) N = 182 | 3 (1.7) N = 174 | |
| Bilateral or multifocal tumor growth, n (%) | 24 (13.4) | 18 (9.7) N = 185 | 19 (10.7) | 0.52 |
| Tumor size, n (%) | 0.09 | |||
| < 4 cm | 62 (39.5) | 61 (37.7) | 68 (42.8) | |
| 4–6 cm | 58 (36.9) | 77 (47.5) | 55 (34.6) | |
| > 6 cm | 37 (23.6) | 24 (14.8) | 36 (22.6) | |
| N = 157 | N = 162 | N = 159 | ||
| Days from imaging to surgery median (Q1–3) | 40 (20–131) N = 175 | 35 (21–73) N = 185 | 34 (20–81) N = 176 | 0.24 |
| Resection (not only biopsy), n (%) | 119 (66.9) N = 178 | 138 (75.0) N = 184 | 128 (73.6) N = 174 | 0.19 |
| Postop re-operation due to complicationb, n (%) | 7 (4.5) N = 157 | 7 (4.3) N = 163 | 14 (8.9) N = 157 | 0.14 |
| Histopathology | 0.19 | |||
| Astrocytoma | 92 (51.4) | 100 (53.8) | 77 (43.5) | |
| Oligodendroglioma | 60 (33.5) | 67 (36.0) | 70 (39.5) | |
| Oligoastrocytoma | 27 (15.1) | 19 (10.2) | 30 (16.9) | |
| Number of comorbidities, n (%) | 0.004 | |||
| 0 | 119 (66.5) | 151 (81.2) | 141 (79.7) | |
| 1 | 36 (20.1) | 27 (14.5) | 28 (15.8) | |
| 2 | 14 (7.8) | 7 (3.8) | 6 (3.4) | |
| 3 or more | 10 (5.6) | 1 (0.5) | 1 (0.6) | |
| N = 179 | N = 186 | N = 177 | ||
Where data are missing, the actual N is provided in individual cells
WHO World Health Organisation, postop postoperatively
aThe WHO/Eastern Cooperative Oncology Group (ECOG) performance score
bAny complication within 30 days postoperatively leading to re-operation (for example parenchymal or extracerebral hemorrhage, infection)
Clinico-pathological factors related to surgical treatment for diffuse, low-grade gliomas in relation to educational levels of patients
| Educational level | ||||
|---|---|---|---|---|
| Lower n = 73 | Intermediate n = 238 | Higher n = 191 | p-value | |
| Age, years, mean (SD) | 52.7 (16.3) | 44.2 (14.1) | 43.2 (12.5) | < 0.01 |
| Asymptomatic, n (%) | 7 (10.0) N = 70 | 18 (8.1) N = 223 | 11 (5.9) N = 187 | 0.49 |
| Focal neurological deficit, n (%) | 29 (40.3) N = 72 | 80 (34.6) N = 231 | 61 (33.0) N = 185 | 0.54 |
| Bilateral or multifocal tumor growth, n (%) | 11 (15.1) | 21 (8.9) N = 237 | 17 (8.9) | 0.26 |
| Tumor size, n (%) | 0.18 | |||
| < 4 cm | 26 (43.3) | 75 (36.4) | 72 (40.9) | |
| 4–6 cm | 24 (40.0) | 93 (45.1) | 60 (34.1) | |
| > 6 cm | 10 (16.7) N = 60 | 38 (18.4) N = 206 | 44 (25.0) N = 176 | |
| WHO performance statusa, n (%) | 0.046 | |||
| 0: Fully active | 32 (45.7) | 130 (56.5) | 126 (66.7) | |
| 1: Light work possible | 23 (32.9) | 63 (27.4) | 40 (21.2) | |
| 2: Cares for self | 11 (15.7) | 32 (13.9) | 20 (10.6) | |
| 3: Limited self-care | 3 (4.3) | 5 (2.2) | 1 (0.5) | |
| 4: Disabled, confined to bed | 1 (1.4) N = 70 | 0 (0.0) N = 230 | 2 (1.1) N = 189 | |
| Days from imaging to surgery, median (Q1–3) | 51 (27–191) | 39 (21–86) N = 235 | 32 (20–80) N = 189 | 0.006 |
| Resection (not only biopsy), n (%) | 46 (64.8) N = 71 | 177 (74.7) N = 237 | 146 (77.7) N = 188 | 0.11 |
| Postop re-operation due to complicationb | 5 (7.6) N = 66 | 6 (2.9) N = 209 | 13 (7.7) N = 160 | 0.08 |
| Histopathology | 0.52 | |||
| Astrocytoma | 34 (46.6) | 125 (52.5) | 85 (44.5) | |
| Oligodendroglioma | 28 (38.3) | 84 (35.3) | 75 (39.3) | |
| Oligoastrocytoma | 11 (15.1) | 29 (12.2) | 31 (16.2) | |
| Number of comorbidities, n (%) | 0.001 | |||
| 0 | 43 (58.9) | 186 (78.2) | 164 (85.9) | |
| 1 | 21 (28.8) | 37 (15.5) | 22 (11.5) | |
| 2 | 6 (8.2) | 10 (4.2) | 4 (2.1) | |
| 3 or more | 3 (4.1) | 5 (2.1) | 1 (0.5) | |
Where data are missing, the actual N is provided in individual cells
WHO World Health Organisation, postop postoperatively
aThe WHO/Eastern Cooperative Oncology Group (ECOG) performance score
bAny complication within 30 days postoperatively leading to re-operation (for example parenchymal or extracerebral hemorrhage, infection)
Fig. 1Waiting time for surgery for diffuse low grade glioma over educational groups (log-rank, p < 0.0001)
Fig. 2Survival after surgery for diffuse low grade glioma according to level of income (log-rank, p = 0.002)
Fig. 3Survival after surgery for diffuse low grade glioma according to level of education (log-rank, p = 0.004)